{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:59:45Z","timestamp":1777687185365,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2017,9,29]]},"DOI":"10.3233\/jhd-170241","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T09:53:51Z","timestamp":1502790831000},"page":"189-199","source":"Crossref","is-referenced-by-count":17,"title":["Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington\u2019s Disease"],"prefix":"10.1177","volume":"6","author":[{"given":"Andrew","family":"McGarry","sequence":"first","affiliation":[{"name":"Cooper University Health Care at Rowan University, Camden, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Kieburtz","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Kansas City, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor D.","family":"Grachev","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Malvern, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Malvern, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Auinger","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Papapetropoulos","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hayden","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Petach Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"4","key":"10.3233\/JHD-170241_ref1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: Natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.3233\/JHD-170241_ref2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2007-971176","article-title":"Huntington\u2019s disease","volume":"27","author":"Walker","year":"2007","journal-title":"Semin Neurol"},{"issue":"8","key":"10.3233\/JHD-170241_ref3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/01.WNL.0000086373.32347.16","article-title":"Huntington\u2019s disease: Clinical correlates of disability and progression","volume":"61","author":"Mahant","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JHD-170241_ref4","first-page":"1817","volume-title":"Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology","author":"Ross","year":"2002"},{"issue":"9557","key":"10.3233\/JHD-170241_ref5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.3233\/JHD-170241_ref6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: The first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"Frank","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.3233\/JHD-170241_ref7","doi-asserted-by":"crossref","unstructured":"Jankovic J , Roos RAC . Chorea associated with Huntington\u2019s disease: To treat or not to treat? Mov Disord 2014;29(11):1414\u201318.","DOI":"10.1002\/mds.25996"},{"issue":"1-3","key":"10.3233\/JHD-170241_ref8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","article-title":"In vivo pharmacology of the dopaminergic stabilizer pridopidine","volume":"644","author":"Ponten","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.3233\/JHD-170241_ref9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1124\/jpet.106.102905","article-title":"The dopamine stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat","volume":"318","author":"Natesan","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.3233\/JHD-170241_ref10","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"J Cell Mol Med"},{"issue":"18","key":"10.3233\/JHD-170241_ref11","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s00213-015-3997-8","article-title":"Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses","volume":"232","author":"Sahlholm","year":"2015","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.3233\/JHD-170241_ref12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/157015908787386113","article-title":"Pharmacology and therapeutic potential of sigma(1) receptor ligands","volume":"6","author":"Cobos","year":"2008","journal-title":"Curr Neuropharmacol"},{"key":"10.3233\/JHD-170241_ref13","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1038\/cddis.2013.170","article-title":"Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: Involvement of calpastatin and the NF-[kappa]B pathway","volume":"4","author":"Hyrskyluoto","year":"2013","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.3233\/JHD-170241_ref14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD: A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.3233\/JHD-170241_ref15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease","volume":"28","author":"Huntington Study Group Hart Investigators","year":"2013","journal-title":"Mov Disord"},{"issue":"1","key":"10.3233\/JHD-170241_ref17","first-page":"17","article-title":"Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken","volume":"54","author":"Fridericia","year":"1921","journal-title":"J Intern Med"},{"issue":"2","key":"10.3233\/JHD-170241_ref18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington\u2019s disease rating scale: Reliability and consistency","volume":"11","author":"Huntington Study Group","year":"1996","journal-title":"Mov Disord"},{"issue":"3","key":"10.3233\/JHD-170241_ref19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25657","article-title":"Tracking motor impairments in the progression of Huntington\u2019s disease","volume":"29","author":"Long","year":"2014","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-170241_ref20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.870100213","article-title":"Functional decline in Huntington\u2019s disease","volume":"10","author":"Feigin","year":"1995","journal-title":"Mov Disord"},{"issue":"1","key":"10.3233\/JHD-170241_ref21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaneurol.2015.2736","article-title":"Clinical-genetic associations in the prospective Huntington at Risk Observational Study (PHAROS): Implications for clinical trials","volume":"73","author":"Biglan","year":"2016","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.3233\/JHD-170241_ref22","first-page":"452","article-title":"Rate of functional decline in Huntington\u2019s disease","volume":"54","author":"Marder","year":"2000","journal-title":"Huntington Study GrouNeurology"},{"issue":"3","key":"10.3233\/JHD-170241_ref24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","author":"Huntington Study Group","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JHD-170241_ref25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-170241_ref27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4088\/PCC.v02n0601","article-title":"Atypical antipsychotic use in the treatment of psychosis in primary care","volume":"2","author":"Leo","year":"2000","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"4","key":"10.3233\/JHD-170241_ref28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1176\/jnp.17.4.496","article-title":"Depression and Stages of Huntington\u2019s Disease","volume":"17","author":"Paulsen","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12","key":"10.3233\/JHD-170241_ref29","first-page":"1520","article-title":"Natural history of Huntington disease","volume":"70","author":"Dorsey","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.3233\/JHD-170241_ref30","first-page":"RRN1184","article-title":"Observing Huntington\u2019s disease: The European Huntington\u2019s Disease Network\u2019s REGISTRY","volume":"2","author":"Orth","year":"2010","journal-title":"PLoS Curr"},{"key":"10.3233\/JHD-170241_ref31","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1212\/WNL.0b013e3182886965","article-title":"One-year safety and tolerability profile of pridopidine in patients with Huntington disease","volume":"80","author":"Squitieri","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JHD-170241_ref32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2014\/273060","article-title":"Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia","volume":"2014","author":"Khasawneh","year":"2014","journal-title":"Cardiol Res Pract"},{"issue":"41","key":"10.3233\/JHD-170241_ref33","first-page":"687","article-title":"QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes","volume":"108","author":"Wenzel-Seifert","year":"2011","journal-title":"Deutsches \u00c4rzteblatt Int"},{"key":"10.3233\/JHD-170241_ref34","doi-asserted-by":"crossref","first-page":"RRN1206","DOI":"10.1371\/currents.RRN1206","article-title":"Utilisation of healthcare and associated services in Huntington\u2019s disease: A data mining study","volume":"3","author":"Busse","year":"2011","journal-title":"PLoS Curr"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-170241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:18Z","timestamp":1777453038000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-170241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":31,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jhd-170241","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]}}}